159 related articles for article (PubMed ID: 38260492)
1. First-in-human imaging with [
Tendler S; Dunphy MP; Agee M; O'Donoghue J; Aly RG; Choudhury NJ; Kesner A; Kirov A; Mauguen A; Baine MK; Schoder H; Weber WA; Rekhtman N; Lyashchenko SK; Bodei L; Morris MJ; Lewis JS; Rudin CM; Poirier JT
medRxiv; 2024 Jan; ():. PubMed ID: 38260492
[TBL] [Abstract][Full Text] [Related]
2. Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3.
Korsen JA; Kalidindi TM; Khitrov S; Samuels ZV; Chakraborty G; Gutierrez JA; Poirier JT; Rudin CM; Chen Y; Morris MJ; Pillarsetty N; Lewis JS
J Nucl Med; 2022 Sep; 63(9):1401-1407. PubMed ID: 35058323
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Comparative
Sharma SK; Adumeau P; Keinänen O; Sisodiya V; Sarvaiya H; Tchelepi R; Korsen JA; Pourat J; Edwards KJ; Ragupathi A; Hamdy O; Saunders LR; Rudin CM; Poirier JT; Lewis JS; Zeglis BM
Bioconjug Chem; 2021 Jul; 32(7):1255-1262. PubMed ID: 33835770
[TBL] [Abstract][Full Text] [Related]
4. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.
Bhattacharyya S; Kurdziel K; Wei L; Riffle L; Kaur G; Hill GC; Jacobs PM; Tatum JL; Doroshow JH; Kalen JD
Nucl Med Biol; 2013 May; 40(4):451-7. PubMed ID: 23454247
[TBL] [Abstract][Full Text] [Related]
5. Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer.
Korsen JA; Gutierrez JA; Tully KM; Carter LM; Samuels ZV; Khitrov S; Poirier JT; Rudin CM; Chen Y; Morris MJ; Bodei L; Pillarsetty N; Lewis JS
Proc Natl Acad Sci U S A; 2022 Jul; 119(27):e2203820119. PubMed ID: 35759660
[TBL] [Abstract][Full Text] [Related]
6. Visualizing Galectin-3 Binding Protein Expression with ImmunoPET.
Keinänen O; Sarrett SM; Delaney S; Rodriguez C; Dayts EJ; Capone E; Sauniere F; Ippoliti R; Sala G; Iacobelli S; Zeglis BM
Mol Pharm; 2023 Jun; 20(6):3241-3248. PubMed ID: 37191353
[TBL] [Abstract][Full Text] [Related]
7. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.
Sharma SK; Pourat J; Abdel-Atti D; Carlin SD; Piersigilli A; Bankovich AJ; Gardner EE; Hamdy O; Isse K; Bheddah S; Sandoval J; Cunanan KM; Johansen EB; Allaj V; Sisodiya V; Liu D; Zeglis BM; Rudin CM; Dylla SJ; Poirier JT; Lewis JS
Cancer Res; 2017 Jul; 77(14):3931-3941. PubMed ID: 28487384
[TBL] [Abstract][Full Text] [Related]
9. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.
Holland JP; Divilov V; Bander NH; Smith-Jones PM; Larson SM; Lewis JS
J Nucl Med; 2010 Aug; 51(8):1293-300. PubMed ID: 20660376
[TBL] [Abstract][Full Text] [Related]
10. CD4
Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
[TBL] [Abstract][Full Text] [Related]
11. Imaging diagnosis and efficacy monitoring by [
He H; Qi X; Fu H; Xu J; Zheng Q; Chen L; Zhang Y; Hua H; Xu W; Xu Z; Chen X; You Q; Lin J; Huang G; Mao Y; Yu C
Theranostics; 2024; 14(1):392-405. PubMed ID: 38164149
[No Abstract] [Full Text] [Related]
12. Site-specifically labeled
Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
[TBL] [Abstract][Full Text] [Related]
13. An
Dietlein F; Kobe C; Vázquez SM; Fischer T; Endepols H; Hohberg M; Reifegerst M; Neumaier B; Schomäcker K; Drzezga AE; Dietlein M
J Nucl Med; 2022 Apr; 63(4):573-583. PubMed ID: 34326129
[TBL] [Abstract][Full Text] [Related]
14.
Wyszatko K; Janzen N; Silva LR; Kwon L; Komal T; Ventura M; Venugopal C; Singh SK; Valliant JF; Sadeghi S
EJNMMI Res; 2024 Mar; 14(1):29. PubMed ID: 38498285
[TBL] [Abstract][Full Text] [Related]
15. CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging.
Ulaner GA; Sobol NB; O'Donoghue JA; Kirov AS; Riedl CC; Min R; Smith E; Carter LM; Lyashchenko SK; Lewis JS; Landgren CO
Radiology; 2020 Jun; 295(3):606-615. PubMed ID: 32255416
[TBL] [Abstract][Full Text] [Related]
16. Phase I/IIa PET imaging study with
Joraku A; Hatano K; Kawai K; Kandori S; Kojima T; Fukumitsu N; Isobe T; Mori Y; Sakata M; Hara T; Nasu K; Minami M; Iizumi Y; Nishiyama H
Ann Nucl Med; 2019 Feb; 33(2):119-127. PubMed ID: 30406361
[TBL] [Abstract][Full Text] [Related]
17. Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer.
Vázquez SM; Endepols H; Fischer T; Tawadros SG; Hohberg M; Zimmermanns B; Dietlein F; Neumaier B; Drzezga A; Dietlein M; Schomäcker K
Mol Imaging Biol; 2022 Feb; 24(1):115-125. PubMed ID: 34370181
[TBL] [Abstract][Full Text] [Related]
18. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing
Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA
Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305
[TBL] [Abstract][Full Text] [Related]
19. First-in-Human Evaluation of Site-Specifically Labeled
Yeh R; O'Donoghue JA; Jayaprakasam VS; Mauguen A; Min R; Park S; Brockway JP; Bromberg JF; Zhi WI; Robson ME; Sanford R; Modi S; Agnew BJ; Lyashchenko SK; Lewis JS; Ulaner GA; Zeglis BM
J Nucl Med; 2024 Mar; 65(3):386-393. PubMed ID: 38272704
[TBL] [Abstract][Full Text] [Related]
20. Light-Induced Radiosynthesis of
Klingler S; Fay R; Holland JP
J Nucl Med; 2020 Jul; 61(7):1072-1078. PubMed ID: 31924725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
